Court grants Amarin long-awaited Vascepa exclusivity

Amarin ($AMRN) has finally grabbed the 5-year marketing exclusivity for fish oil pill Vascepa that it's long been seeking. On Thursday, a U.S. district court ruled that it's eligible, setting aside an FDA decision from last February. Shares of the Irish drugmaker soared as much as 44% on the news, Reuters reports. Story